In their study including 14 patients with pancreatic adenocarcinoma, Watanabe et al7 observed that HMGA2 and vimentin expression increased while E-cadherin expression decreased using Western blot analysis when the RAS/MEK pathway was inhibited. The gene discussed is HMGA2; the disease is pancreatic adenocarcinoma.